{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:39Z","timestamp":1790812119424,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22075127"],"award-info":[{"award-number":["22075127"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22275080"],"award-info":[{"award-number":["22275080"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773291"],"award-info":[{"award-number":["81773291"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515011638"],"award-info":[{"award-number":["2021A1515011638"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012044"],"award-info":[{"award-number":["2022A1515012044"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jconrel.2023.03.017","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T12:28:40Z","timestamp":1679574520000},"page":"691-701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer"],"prefix":"10.1016","volume":"356","author":[{"given":"Xiaomei","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujiang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Bing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.03.017_bb0005","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/d41586-018-07188-1","article-title":"A new road to cancer-drug resistance","volume":"563","author":"Schlacher","year":"2018","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0010","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S1470-2045(11)70335-7","article-title":"Genetic heterogeneity and cancer drug resistance","volume":"13","author":"Turner","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jconrel.2022.03.049","article-title":"Targeted nanomedicine in cisplatin-based cancer therapeutics","volume":"345","author":"Han","year":"2022","journal-title":"J. Control. Rel.: Off. J. Control. Rel. Soc."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0020","first-page":"20","article-title":"New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment","volume":"20","author":"Chen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0025","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.3390\/cancers13215480","article-title":"Nano-based drug delivery and targeting to overcome drug resistance of ovarian cancers","volume":"13","author":"McFadden","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2023.03.017_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100704","article-title":"Nanomedicine to target multidrug resistant tumors","volume":"52","author":"Lepeltier","year":"2020","journal-title":"Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0035","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","article-title":"Smart cancer nanomedicine","volume":"14","author":"van der Meel","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0040","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.7150\/thno.53828","article-title":"Biocompatible AIEgen\/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer","volume":"11","author":"Wu","year":"2021","journal-title":"Theranostics."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0045","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.nano.2016.11.010","article-title":"Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models","volume":"13","author":"Roberts","year":"2017","journal-title":"Nanomed.: Nanotechnol. Biol. Med."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jconrel.2019.01.011","article-title":"Combinatorial nanocarriers against drug resistance in hematological cancers: opportunities and emerging strategies","volume":"296","author":"Ghosh","year":"2019","journal-title":"J. Control. Rel.: Off. J. Control. Rel. Soc."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0055","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.trecan.2019.02.003","article-title":"Polytherapy and targeted cancer drug resistance","volume":"5","author":"Chatterjee","year":"2019","journal-title":"Trends Cancer."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0060","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Sig. Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0065","doi-asserted-by":"crossref","first-page":"38417","DOI":"10.1021\/acsami.9b12140","article-title":"pH-sensitive Shell-Core platform block DNA repair pathway to amplify irreversible DNA damage of triple negative breast cancer","volume":"11","author":"Dong","year":"2019","journal-title":"ACS Appl. Mater. Interfaces."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0070","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.3390\/molecules23123217","article-title":"Demethoxycurcumin-loaded Chitosan nanoparticle downregulates DNA repair pathway to improve Cisplatin-induced apoptosis in non-small cell lung cancer","volume":"23","author":"Chen","year":"2018","journal-title":"Mol. (Basel, Switzerl)."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0075","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.nano.2017.06.004","article-title":"Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma","volume":"13","author":"Kievit","year":"2017","journal-title":"Nanomedicine."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2018.03.055","article-title":"Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models","volume":"169","author":"Zhang","year":"2018","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0085","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0090","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0095","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0100","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10131","article-title":"Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer","volume":"4","author":"Mensah","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0110","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1039\/C9BM00797K","article-title":"Enhancement of cisplatin efficacy by lipid-CaO(2) nanocarrier-mediated comprehensive modulation of the tumor microenvironment","volume":"7","author":"He","year":"2019","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.gene.2018.04.033","article-title":"HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells","volume":"663","author":"Li","year":"2018","journal-title":"Gene."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ptr.6798","article-title":"Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells","volume":"35","author":"Zhao","year":"2021","journal-title":"Phytother. Res.: PTR."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0125","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1007\/s00018-020-03559-y","article-title":"Heparanase, cell signaling, and viral infections","volume":"77","author":"Koganti","year":"2020","journal-title":"Cell. Mol. Life Sci.: CMLS."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0130","doi-asserted-by":"crossref","first-page":"12366","DOI":"10.1074\/jbc.M112.435172","article-title":"Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence","volume":"288","author":"Riaz","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0135","first-page":"179","article-title":"Self-anti-angiogenesis nanoparticles enhance anti-metastatic-tumor efficacy of chemotherapeutics","volume":"13","author":"Luo","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.actbio.2019.06.039","article-title":"cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer","volume":"94","author":"Wang","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0145","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1021\/mp3002733","article-title":"RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis","volume":"9","author":"Danhier","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0150","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrc2353","article-title":"Integrins in angiogenesis and lymphangiogenesis","volume":"8","author":"Avraamides","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2023.03.017_bb0155","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.7512751","article-title":"Requirement of vascular integrin alpha v beta 3 for angiogenesis","volume":"264","author":"Brooks","year":"1994","journal-title":"Science (New York, N.Y.)."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0160","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1038\/s41598-017-07617-7","article-title":"H-ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer","volume":"7","author":"Mazzucchelli","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0165","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0168-3659(95)00165-4","article-title":"Introduction of cisplatin into polymeric micelle","volume":"39","author":"Yokoyama","year":"1996","journal-title":"J. Control. Release."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22853","article-title":"Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1\/PI3K\/mTOR signaling pathway","volume":"35","author":"Ma","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0175","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/s41598-019-38667-8","article-title":"Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer","author":"Myint","year":"2019","journal-title":"Sci. Rep. 9"},{"key":"10.1016\/j.jconrel.2023.03.017_bb0180","article-title":"Lemon-derived extracellular vesicles nanodrugs enable to efficiently overcome cancer multidrug resistance by endocytosis-triggered energy dissipation and energy production reduction","volume":"9","author":"Xiao","year":"2022","journal-title":"Adv. Sci. (Weinh)."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12974-017-0912-8","article-title":"Heparanase promotes neuroinflammatory response during subarachnoid hemorrhage in rats","volume":"14","author":"Changyaleket","year":"2017","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0190","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1021\/bc8003809","article-title":"Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity","volume":"20","author":"Wang","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0195","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bmcl.2008.10.132","article-title":"A model ternary heparin conjugate by direct covalent bond strategy applied to drug delivery system","volume":"19","author":"Wang","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2011.12.025","article-title":"Use of the \u03b3-H2AX assay to monitor DNA damage and repair in translational cancer research","volume":"327","author":"Ivashkevich","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0205","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.3390\/ijms22083948","article-title":"Molecular imaging of apoptosis: the case of Caspase-3 radiotracers","volume":"22","author":"Beroske","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0210","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00412-018-0659-8","article-title":"Ki-67: more than a proliferation marker","volume":"127","author":"Sun","year":"2018","journal-title":"Chromosoma."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0215","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bjorl.2019.10.009","article-title":"The role of MMP-2 and MMP-9 in the metastasis and development of hypopharyngeal carcinoma","volume":"87","author":"Song","year":"2021","journal-title":"Brazil. J. Otorhinolaryngol."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0220","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.semcancer.2019.07.014","article-title":"Role of heparanase in tumor progression: molecular aspects and therapeutic options","volume":"62","author":"Masola","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0225","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3389\/fonc.2019.01316","article-title":"Heparanase: a challenging cancer drug target","volume":"9","author":"Coombe","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2023.03.017_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114205","article-title":"Therapeutic strategies to overcome cisplatin resistance in ovarian cancer","volume":"232","author":"Song","year":"2022","journal-title":"Eur. J. Med. Chem."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923001840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923001840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:43:01Z","timestamp":1759164181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923001840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":46,"alternative-id":["S0168365923001840"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.03.017","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}